Literature DB >> 13953686

[Studies on controlled radiotherapy of melanoma and on the chromaffin system by selective H-3 incorporation after administration of H-3-labelled DOPA].

K HEMPEL, M DEIMEL.   

Abstract

Entities:  

Keywords:  CHROMAFFIN SYSTEM; DOPA; MELANOMA; RADIOAUTOGRAPHY; RADIOMETRY

Mesh：

Substances：

Year:  1963        PMID： 13953686

Source DB:  PubMed          Journal:  Strahlentherapie        ISSN： 0039-2073


× No keyword cloud information.
  7 in total

1.  [EFFECT OF THE DOPA-DECARBOXYLASE INHIBITOR ALPHA-METHYLDOPA ON THE INCORPORATION OF DOPA INTO MELANIN AND PYROCATECHOLAMINE. IN VIVO STUDIES ON MELANOMA MICE WITH TRITIATED DOPA].

Authors:  K HEMPEL; M DEIMEL
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1963-11-08

2.  [Autoradiographic examinations of the metabolic activity of the carotid body].

Authors:  B Helpap
Journal:  Arch Klin Exp Ohren Nasen Kehlkopfheilkd       Date:  1970

3.  [Simultaneous histochemical and autoradiographic demonstration of catecholamines in cryostat sections].

Authors:  J Winckler; K Hempel
Journal:  Histochemie       Date:  1971

4.  Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas.

Authors:  G Kloss; M Leven
Journal:  Eur J Nucl Med       Date:  1979-06-01

5.  The incorporation of 51Cr-3, 4-dihydroxyphenylalanine (DOPA) complex into melanoma B 16.

Authors:  L J Anghileri; E S Miller
Journal:  Z Krebsforsch       Date:  1970-11-20

6.  Potential radiopharmaceuticals for the detection of ocular melanoma. Part III. A study with 14C and 11C labelled tyrosine and dihydroxyphenylalanine.

Authors:  A van Langevelde; H D van der Molen; J G Journée-de Korver; A M Paans; E K Pauwels; W Vaalburg
Journal:  Eur J Nucl Med       Date:  1988

7.  [Hamster melanoma M Mel 1 as an ascites tumor. II. Research on the therapeutic possibilities in this ascites melanoma. Comparison with therapeutic effects in other melanomas].

Authors:  F Ott
Journal:  Arch Klin Exp Dermatol       Date:  1969
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.